Novel cancer vaccine targets oncogenes known to evade immunity in melanoma and neuroblastoma models
Cardiovascular risk factors tied to poor pregnancy outcomes
2 April 2021Study sheds light on interplay among PTSD, combat experience, alcohol use
2 April 2021Novel cancer vaccine targets oncogenes known to evade immunity in melanoma and neuroblastoma models
A personalized tumor cell vaccine strategy targeting Myc oncogenes combined with checkpoint therapy creates an effective immune response that bypasses antigen selection and immune privilege, according to a pre-clinical study for neuroblastoma and melanoma. The neuroblastoma model showed a 75% cure with long-term survival, researchers at Children’s National Hospital found.
